Shares of Harrow, Inc. (NASDAQ:HROW - Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $23.32, but opened at $28.93. Harrow shares last traded at $28.87, with a volume of 570,497 shares traded.
Wall Street Analysts Forecast Growth
A number of analysts recently weighed in on HROW shares. B. Riley cut their price target on shares of Harrow from $73.00 to $69.00 and set a "buy" rating on the stock in a research report on Wednesday, December 4th. HC Wainwright reaffirmed a "buy" rating and set a $57.00 price objective on shares of Harrow in a research note on Tuesday.
Get Our Latest Report on HROW
Harrow Price Performance
The company's fifty day moving average price is $29.51 and its two-hundred day moving average price is $38.40. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. The company has a market cap of $1.01 billion, a price-to-earnings ratio of -30.22 and a beta of 0.69.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of the company. Quest Partners LLC bought a new stake in Harrow in the 3rd quarter valued at approximately $29,000. GF Fund Management CO. LTD. bought a new stake in Harrow during the 4th quarter worth about $25,000. Tower Research Capital LLC TRC boosted its stake in shares of Harrow by 769.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock worth $55,000 after buying an additional 1,462 shares during the last quarter. Aquatic Capital Management LLC acquired a new stake in shares of Harrow in the fourth quarter valued at about $78,000. Finally, AlphaQuest LLC raised its holdings in Harrow by 452.8% during the fourth quarter. AlphaQuest LLC now owns 3,527 shares of the company's stock worth $118,000 after acquiring an additional 2,889 shares in the last quarter. 72.76% of the stock is owned by institutional investors and hedge funds.
About Harrow
(
Get Free Report)
Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.
See Also
Before you consider Harrow, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harrow wasn't on the list.
While Harrow currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
